154 related articles for article (PubMed ID: 26221412)
1. Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.
Fu Y; Kang H; Zhao H; Hu J; Zhang H; Li X; Du N; Huang Y
Int J Clin Exp Med; 2015; 8(5):8288-94. PubMed ID: 26221412
[TBL] [Abstract][Full Text] [Related]
2. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
5. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
6. A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure.
Xiao W; Que Y; Peng R; Ding Y; Zhao J; Wen X; Weng D; Zhang X; Guan Y; Zhang X
Onco Targets Ther; 2018; 11():2439-2443. PubMed ID: 29760553
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
[TBL] [Abstract][Full Text] [Related]
9. Advanced dermatofibrosarcoma protuberans: an updated analysis of cases from an Indian sarcoma clinic.
Rasheed AA; Barwad A; Dhamija E; Garg R; Pandey R; Shamim SA; Arun Raj ST; Rastogi S
Future Sci OA; 2021 Oct; 7(9):FSO743. PubMed ID: 34737884
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.
Beaziz J; Battistella M; Delyon J; Farges C; Marco O; Pages C; Le Maignan C; Da Meda L; Basset-Seguin N; Resche-Rigon M; Walter Petrich A; Kérob D; Lebbé C; Baroudjian B
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066400
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors - a real-world multi-center study.
Huang S; Liu X; Guo X; Wu H; Lu H; Pan Z; Cai S; Wu X; Zhang X
Transl Oncol; 2023 Apr; 30():101641. PubMed ID: 36791510
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
15. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
16. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST).
Rutkowski P; Jagielska B; Andrzejuk J; Bylina E; Lugowska I; Switaj T; Kosela-Paterczyk H; Kozak K; Falkowski S; Klimczak A
Contemp Oncol (Pozn); 2017; 21(4):285-289. PubMed ID: 29416434
[TBL] [Abstract][Full Text] [Related]
17. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018.
Ugurel S; Kortmann RD; Mohr P; Mentzel T; Garbe C; Breuninger H; Bauer S; Grabbe S
J Dtsch Dermatol Ges; 2019 Jun; 17(6):663-668. PubMed ID: 31115967
[TBL] [Abstract][Full Text] [Related]
18. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C
Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
